Henry Fechner

List of Publications by Year
in descending order

48 papers	1,439 citations	430874 18 h-index	345221 36 g-index
50 all docs	50 docs citations	50 times ranked	2064 citing authors

#	Article	IF	Citations
1	Long-Term Cardiac-Targeted RNA Interference for the Treatment of Heart Failure Restores Cardiac Function and Reduces Pathological Hypertrophy. Circulation, 2009, 119, 1241-1252.	1.6	200
2	Generation of a 3D Liver Model Comprising Human Extracellular Matrix in an Alginate/Gelatin-Based Bioink by Extrusion Bioprinting for Infection and Transduction Studies. International Journal of Molecular Sciences, 2018, 19, 3129.	4.1	107
3	Induction of Coxsackievirus-Adenovirusâ€“Receptor Expression During Myocardial Tissue Formation and Remodeling. Circulation, 2003, 107, 876-882.	1.6	91
4	Cardiac-targeted RNA interference mediated by an AAV9 vector improves cardiac function in coxsackievirus B3 cardiomyopathy. Journal of Molecular Medicine, 2008, 86, 987-997.	3.9	73
5	Prevention of Cardiac Dysfunction in Acute Coxsackievirus B3 Cardiomyopathy by Inducible Expression of a Soluble Coxsackievirus-Adenovirus Receptor. Circulation, 2009, 120, 2358-2366.	1.6	67
6	Antibody-Mediated Enhancement of Parvovirus B19 Uptake into Endothelial Cells Mediated by a Receptor for Complement Factor C1q. Journal of Virology, 2014, 88, 8102-8115.	3.4	65
7	MicroRNA-regulated viral vectors for gene therapy. World Journal of Experimental Medicine, 2016, 6, 37.	1.7	64
8	NOD2 (Nucleotide-Binding Oligomerization Domain 2) Is a Major Pathogenic Mediator of Coxsackievirus B3-Induced Myocarditis. Circulation: Heart Failure, 2017, 10, .	3.9	60
9	Virus-Host Coevolution in a Persistently Coxsackievirus B3-Infected Cardiomyocyte Cell Line. Journal of Virology, 2011, 85, 13409-13419.	3.4	45
10	Immunomodulation by adoptive regulatory Tâ€cell transfer improves Coxsackievirus B3â€induced myocarditis. FASEB Journal, 2018, 32, 6066-6078.	0.5	42
11	Cardiac-targeted delivery of regulatory RNA molecules and genes for the treatment of heart failure. Cardiovascular Research, 2010, 86, 353-364.	3.8	39
12	Molecular characterisation of the defective Î±1-antitrypsin alleles PI MwÃ¼rzburg (Pro369Ser), Mheerlen (Pro369Leu), and Q0lisbon (Thr68Ile). European Journal of Human Genetics, 1999, 7, 321-331.	2.8	37
13	Pharmacological and Biological Antiviral Therapeutics for Cardiac Coxsackievirus Infections. Molecules, 2011, 16, 8475-8503.	3.8	33
14	Application of Mutated miR-206 Target Sites Enables Skeletal Muscle-specific Silencing of Transgene Expression of Cardiotropic AAV9 Vectors. Molecular Therapy, 2013, 21, 924-933.	8.2	30
15	Inhibition of adenovirus infections by siRNA-mediated silencing of early and late adenoviral gene functions. Antiviral Research, 2010, 88, 86-94.	4.1	27
16	Protein modification with ISG15 blocks coxsackievirus pathology by antiviral and metabolic reprogramming. Science Advances, 2020, 6, eaay1109.	10.3	27
17	Vaccine protection against lethal homologous and heterologous challenge using recombinant AAV vectors expressing codon-optimized genes from pandemic swine origin influenza virus (SOIV). Vaccine, 2011, 29, 1690-1699.	3.8	25
18	Combination of soluble coxsackievirus-adenovirus receptor and anti-coxsackievirus siRNAs exerts synergistic antiviral activity against coxsackievirus B3. Antiviral Research, 2009, 83, 298-306.	4.1	24

#	Article	IF	Citations
19	Colchicine prevents disease progression in viral myocarditis via modulating the NLRP3 inflammasome in the cardiosplenic axis. ESC Heart Failure, 2022, 9, 925-941.	3.1	23
20	A Novel Artificial MicroRNA Expressing AAV Vector for Phospholamban Silencing in Cardiomyocytes Improves Ca2+ Uptake into the Sarcoplasmic Reticulum. PLoS ONE, 2014, 9, e92188.	2.5	19
21	Virotherapy Research in Germany: From Engineering to Translation. Human Gene Therapy, 2017, 28, 800-819.	2.7	19
22	Heparan Sulfate Binding Coxsackievirus B3 Strain PD: A Novel Avirulent Oncolytic Agent Against Human Colorectal Carcinoma. Human Gene Therapy, 2018, 29, 1301-1314.	2.7	19
23	Virotherapy in Germanyâ€"Recent Activities in Virus Engineering, Preclinical Development, and Clinical Studies. Viruses, 2021, 13, 1420.	3.3	19
24	Anti-adenoviral Artificial MicroRNAs Expressed from AAV9 Vectors Inhibit Human Adenovirus Infection in Immunosuppressed Syrian Hamsters. Molecular Therapy - Nucleic Acids, 2017, 8, 300-316.	5.1	18
25	Combination of RNA Interference and Virus Receptor Trap Exerts Additive Antiviral Activity in Coxsackievirus B3-induced Myocarditis in Mice. Journal of Infectious Diseases, 2015, 211, 613-622.	4.0	17
26	Coxsackievirus B3â€"Its Potential as an Oncolytic Virus. Viruses, 2021, 13, 718.	3.3	17
27	Development of a new mouse model for coxsackievirus-induced myocarditis by attenuating coxsackievirus B3 virulence in the pancreas. Cardiovascular Research, 2020, 116, 1756-1766.	3.8	16
28	Application of modified antisense oligonucleotides and siRNAs as antiviral drugs. Future Medicinal Chemistry, 2015, 7, 1637-1642.	2.3	15
29	The Coxsackievirus and Adenovirus Receptor: Glycosylation and the Extracellular D2 Domain Are Not Required for Coxsackievirus B3 Infection. Journal of Virology, 2016, 90, 5601-5610.	3.4	15
30	Infection of iPSC Lines with Miscarriage-Associated Coxsackievirus and Measles Virus and Teratogenic Rubella Virus as a Model for Viral Impairment of Early Human Embryogenesis. ACS Infectious Diseases, 2017, 3, 886-897.	3.8	15
31	Early Treatment of Coxsackievirus B3â€"Infected Animals With Soluble Coxsackievirus-Adenovirus Receptor Inhibits Development of Chronic Coxsackievirus B3 Cardiomyopathy. Circulation: Heart Failure, 2019, 12, e005250.	3.9	14
32	miR-375- and miR-1-Regulated Coxsackievirus B3 Has No Pancreas and Heart Toxicity But Strong Antitumor Efficiency in Colorectal Carcinomas. Human Gene Therapy, 2021, 32, 216-230.	2.7	14
33	A bidirectional Tet-dependent promotor construct regulating the expression of E1A for tight control of oncolytic adenovirus replication. Journal of Biotechnology, 2007, 127, 560-574.	3.8	13
34	Efficient Melanoma Cell Killing and Reduced Melanoma Growth in Mice by a Selective Replicating Adenovirus Armed with Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand. Human Gene Therapy, 2011, 22, 405-417.	2.7	13
35	Enhanced suppression of adenovirus replication by triple combination of anti-adenoviral siRNAs, soluble adenovirus receptor trap sCAR-Fc and cidofovir. Antiviral Research, 2015, 120, 72-78.	4.1	13
36	Biological antivirals for treatment of adenovirus infections. Antiviral Therapy, 2016, 21, 559-566.	1.0	13

#	Article	IF	Citations
37	Soluble coxsackie- and adenovirus receptor (sCAR-Fc); a highly efficient compound against laboratory and clinical strains of coxsackie-B-virus. Antiviral Research, 2016, 136, 1-8.	4.1	13
38	Variability in Cardiac miRNA-122 Level Determines Therapeutic Potential of miRNA-Regulated AAV Vectors. Molecular Therapy - Methods and Clinical Development, 2020, 17, 1190-1201.	4.1	13
39	A Novel Method for the Quantification of Adeno-Associated Virus Vectors for RNA Interference Applications Using Quantitative Polymerase Chain Reaction and Purified Genomic Adeno-Associated Virus DNA as a Standard. Human Gene Therapy Methods, 2013, 24, 355-363.	2.1	11
40	Mclâ€1 targeting strategies unlock the proapoptotic potential of TRAIL in melanoma cells. Molecular Carcinogenesis, 2020, 59, 1256-1268.	2.7	11
41	MiRâ€375â€mediated suppression of engineered coxsackievirus B3 in pancreatic cells. FEBS Letters, 2020, 594, 763-775.	2.8	9
42	Use of a three-dimensional humanized liver model for the study of viral gene vectors. Journal of Biotechnology, 2015, 212, 134-143.	3.8	7
43	Study of Viral Vectors in a Three-dimensional Liver Model Repopulated with the Human Hepatocellular Carcinoma Cell Line HepG2. Journal of Visualized Experiments, 2016, , .	0.3	7
44	Silencing Genes in the Heart. Methods in Molecular Biology, 2017, 1521, 17-39.	0.9	5
45	RNA interference-based functional knockdown of the voltage-gated potassium channel Kv7.2 in dorsal root ganglion neurons after in vitro and in vivo gene transfer by adeno-associated virus vectors. Molecular Pain, 2018, 14, 174480691774966.	2.1	5
46	Application Route and Immune Status of the Host Determine Safety and Oncolytic Activity of Oncolytic Coxsackievirus B3 Variant PD-H. Viruses, 2021, 13, 1918.	3.3	4
47	Silencing of Mcl-1 overcomes resistance of melanoma cells against TRAIL-armed oncolytic adenovirus by enhancement of apoptosis. Journal of Molecular Medicine, 2021, 99, 1279-1291.	3.9	3
48	Single-Point Mutations within the Coxsackie B Virus Receptor-Binding Site Promote Resistance against Soluble Virus Receptor Traps. Journal of Virology, 2020, 94, .	3.4	2